MONTREAL, May 9, 2017 /PRNewswire/ - Caprion Biosciences Inc. a worldwide leading specialty CRO laboratory announced today that Dr. Laura McIntosh, PhD, Vice-President of Translational Research and Dr. Michael Schirm, PhD, Associate Director, R&D Proteomics will participate in the upcoming BEBPA Conference in San Francisco, May 10-12, 2017.
Caprion Biosciences Inc., a leader in mass spectrometry analysis applied to proteomics offers comprehensive services to identify and track host cell protein (HCP) present in biological substances. Through its HCP Detect Technology, Caprion Biosciences widely deploys characterization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins, vaccines and peptides to optimize the manufacturing process and batch to batch monitoring of product quality and consistency.
Dr. McIntosh's platform presentation, on Thursday May 11th, at 12 p.m. entitled "HCP Analysis of a Variety of Biologics and Biosimilars using LC-MS/MS", will present Caprion's leading expertise using mass spectrometry workflows for the identification and quantitation of low abundance HCP in biopharmaceutical biological products. In addition, Dr. McIntosh will highlight Innovative approaches to analytical design, bioinformatics and tailored data interpretation with regards to HCP detection and monitoring.
Dr. Schirm's presentation entitled "Data Analysis, Quantitation and Reporting for Mass Spectrometry-Based HCP Studies" will be held at the workshop at 4:30 p.m. on Wednesday May 10th and will provide an overview of case studies illustrating how data analysis, quantitation and reporting can be performed for various HCP applications, including characterization of in-process samples and bulk drug substance, comparability studies of biosimilars to innovators, and absolute quantification of HCP.
ABOUT BIOLOGICS AND PROCESS-RELATED HCP IMPURITIES
Host-cell proteins (HCP) constitute a major part of process-related impurities during biologics production and represent significant clinical safety risk associated to serious adverse events caused by immunogenicity. According to international guidelines issued by various regulatory agencies, rigorous and consistent methods to identify, measure and monitor residual HCP impurities should be implemented. Detecting low abundance HCP in drug substance (DS) remains a challenge which can be addressed with high sensitivity/high coverage characterization methods such as mass spectrometry, contributing to a robust, well-controlled and reproducible bioprocess. HCP impurities can now be readily identified and tracked with high sensitivity using Caprion's HCP DETECT Technology.
Pre-Conference Workshop: Data Analysis, Quantitation and Reporting for Mass Spectrometry-Based HCP Studies
Speaker: Michael Schirm, PhD, Associate Director, R&D Proteomics
Pre-Conference, Wednesday, May 10th, 2017, 4:30 p.m.
Platform Presentation: Lesson's Learned: HCP Analysis of a Variety of Biologics and Biosimilars using LC-MS/MS
Speaker: Laura McIntosh, PhD, Vice-President of Translational Research
Day 1, Thursday, May 11th, 2017, 12:00 p.m.
ABOUT CAPRION BIOSCIENCES, INC.
Founded in 2002, Caprion is a leading specialty CRO laboratory providing an integrated platform in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and in Gosselies, Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP. For more information, please visit www.caprion.com
SOURCE Caprion Biosciences